次世代基因定序（NGS）及患者來源腫瘤類器官（PDO）指導治療於晚期／不可手術實體瘤患者中的前瞻性臨床驗證

納入條件

• patients with metastatic, inoperable or advanced solid tumors who are refractory to at least one standard chemo- or targeted drugs.
• The disease is accessible for a biopsy (radiologic or endoscopic) or resection of a metastatic site.
• These patients are seen at a multidisciplinary tumor board meeting prior to referrals.
• aged \>18 years, able to provide written consents to trial participation,
• with an Eastern cooperative oncology group performance status of 0 or 1,
• with measurable disease in accordance with response evaluation criteria in solid tumors (RECIST) version 1.1.
• deem suitable for standard chemo-therapy; i.e. with a normal neutrophil count, hemoglobin \> 9g/dl, serum creatinine, \<1.5 x upper limit of normal, bilirubin \< 1.5 x normal, Aspartate and alanine aminotransferases (\<3 x ULN or \<5x
• those with liver metastasis) and with an ejection Fraction \>50% of normal on echocardiography.